文献速递前列腺癌

PSA时代432例50岁以下前列腺癌患者的临床特征与治疗结局

Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlook.
PubMed 文献 · BJU Int · 2018-11-08

该回顾性研究分析了1994至2017年间432例50岁以下前列腺癌患者的临床特征与治疗结局。结果显示多数患者为低危或中危疾病,根治性前列腺切除术后5年生化复发率低于D'Amico模型预测,主动监测在低危患者中安全,仅0.4%死于前列腺癌。

要点

  • 50岁以下患者中低危占44%、中危42%、高危13%,仅2.0%初诊即转移。
  • 根治性前列腺切除术后5年生化复发率低危7.8%、中危15.3%、高危23.3%。
  • 低危患者主动监测后仅17.6%需根治治疗,中位随访46个月,手术病理与立即手术者无显著差异。

核心结论

  • PSA时代年轻前列腺癌患者多表现为较低危疾病,根治术后5年生化复发率令人安心,低危患者主动监测安全。

主要发现

  • 44%低危、42%中危、13%高危,中位年龄47岁,39.1%有前列腺癌家族史。
  • 临床分期T1占65.5%、T2占30.0%,2.0%初诊即有转移。
  • 78.4%(339例)行根治性前列腺切除术,5年生化复发率低危7.8%、中危15.3%、高危23.3%,低于D'Amico模型预测及年龄匹配的老年患者。
  • 74例低危患者接受主动监测,中位随访46个月后仅17.6%(13例)需根治治疗,手术病理(切缘阳性P=0.145、肿瘤体积P=0.257、精囊侵犯P=0.100)与立即手术的低危患者无显著差异。
  • 中位随访65个月,仅0.4%死于前列腺癌。

临床怎么用

  • 年轻前列腺癌患者应依据危险分层选择治疗,低危者可考虑主动监测。
  • 根治性前列腺切除术后生化复发率低于传统预测模型,预后咨询可参考本研究数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the clinical presentation and treatment outcomes of prostate cancer (PCa) in 432 consecutive patients aged < 50 years in the prostate-specific antigen (PSA) era. METHODS: Retrospective analysis was performed on all patients with PCa (14 570) from the years 1994 to 2017. A total of 432 consecutive patients aged < 50 years were identified. The patients were stratified by D'Amico risk groups, and their clinical presentation and treatment outcomes were analysed. The rates of biochemical recurrence after surgery were compared with the D'Amico prediction model as well as with older propensity-score-matched patients. The surgical pathology results in patients undergoing active surveillance (AS) were compared with those of low-risk patients who underwent immediate surgery. RESULTS: A total of 44%, 42% and 13% of patients harboured low-risk, intermediate-risk and high-risk PCa, respectively. Their median age was 47 years and a positive family history of PCa was reported in 39.1%. Clinical stage was T1 in 65.5% and T2 in 30.0% of patients, and 2.0% of patients had metastatic disease at presentation. Radical prostatectomy (RP) was performed in 78.4% of patients (n = 339) and the biochemical recurrence rates were 7.8% (low-risk), 15.3% (intermediate-risk) and 23.3% (high-risk) at 5 years post-surgery. These rates were lower than expected according to the D'Amico prediction model or when compared with older matched patients. A total of 74 patients with low-risk PCa underwent AS and only 17.6% (n = 13) required radical treatment after a median follow-up of 46 months. The surgical pathology results in patients undergoing ASdid not differ significantly from patients with low-risk PCa who underwent immediate surgery (positive surgical margins [P = 0.145], tumour volume [P = 0.257] or seminal vesicle involvement [P = 0.100]). Of the present cohort, only 0.4% died from PCa during a median follow-up of 65 months. CONCLUSIONS: The clinical presentation and prognosis of young patients has changed dramatically during the PSA era. Patients nowadays present with lower-risk disease that can be treated adequately, with reassuring biochemical recurrence rates at 5 years post-surgery. AS appears to be safe in patients with low-risk. PCa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Gielchinsky I, Chang J, Cusick T, et al. Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlook. BJU Int. 2018. PMID: 30303599. doi:10.1111/bju.14586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。